By Colin Kellaher
AbbVie’s antiwrinkle treatment, Botox, has successfully demonstrated its effectiveness in a second late-stage study focused on addressing the issue of platysma prominence. This condition, which impacts the neck, jawline, and lower face, is a common part of the aging process.
Allergan, a subsidiary of AbbVie, announced on Monday that their Phase 3 clinical trial involving Botox for the treatment of moderate-to-severe platysma prominence has achieved all primary and secondary goals. These results align with the findings from a previous Phase 3 study.
The comprehensive data from this study will be included in a regulatory submission to the U.S. Food and Drug Administration (FDA) at the end of this year. Allergan is optimistic about gaining FDA approval, which would make Botox the first and only neurotoxin officially recognized for addressing platysma prominence. This condition arises from the contraction of a superficial, flat muscle in the lower face and neck.
Originally approved by the FDA in 1989 to address rare eye muscle disorders, Botox has since received regulatory clearance for various cosmetic and therapeutic uses. In the first half of 2023, AbbVie reported over $2.8 billion in combined revenue from Botox’s cosmetic and therapeutic applications.